Please ensure Javascript is enabled for purposes of website accessibility

Why Celgene Corporation Tumbled Today

By Brian Orelli, PhD - Oct 26, 2017 at 1:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech revised long-term guidance lower, but the growth prospects still look promising.

What happened

Celgene (CELG) is down 18.2% at 12:11 p.m. Thursday after releasing third-quarter earnings. It wasn't so much third-quarter revenue, which was up 10% year over year, or the adjusted earnings per share, which jumped 21% year over year, but the lowered guidance that has investors concerned.

So what

The biotech adjusted both 2017 guidance and its long-term 2020 guidance that was originally given in early 2015, although it was the latter that was most concerning.

This year, Celgene is looking for revenue of "approximately $13 billion," which is at the low end of the previous guidance for revenue to fall between $13 billion and $13.4 billion. The lower expectations are due to a decrease in the expected sales of its anti-inflammatory drug Otezla by $250 million to $450 million. Guidance for adjusted earnings was actually moved to the high end of previous guidance, with current expectations to come in at $7.30 to $7.35 per share.

For 2020, Celgene expects product sales between $19 billion and $20 billion, down from previous guidance of more than $21 billion. Hematology sales are expected to be higher than previous expectations, but they can't make up for a sharp decline in inflammation and immunology (I&I) drugs, which were expected to exceed $4 billion, but which Celgene now hopes will fall in the $2.6 billion to $2.8 billion range. The slower Otezla sales plus the loss of GED-0301 in Crohn's disease is clearly hurting the I&I category. Expectations for Celgene's oncology drugs also went down from more than $2.2 billion previously to a range of $1 billion to $1.1 billion.

On the bottom line, Celgene expects adjusted earnings of more than $12.50 per share, down from previous guidance of more than $13.00 per share.

Red button with 2020 on it

Investors hit the 2020 panic button.
Image source: Getty Images.

Now what

The reduced guidance is certainly disappointing, especially for a company that tends to be conservative, so investors have become accustomed to seeing guidance increased throughout the year.

But even at the low end of guidance, Celgene's management thinks it can grow revenue by 46% from 2017 to 2020; that's 13.5% compounded annually. And adjusted earnings are expected to increase by about 70% over those three years -- a 19.5% compound annual growth rate.

Despite the decreased guidance, those growth numbers don't look too bad. Let's just hope they're based on management's usual conservativeness.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celgene Corporation Stock Quote
Celgene Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.